最新发布
Apeel founder on MAHA, misinformation, layoffs, and a second act in post-harvest tech
[Disclosure: AgFunderNews’ parent company is an investor in Impact Vision, a startup acquired by Apeel Sciences in 2021]…
解密2026生物制剂新风口,诚邀您的品牌共探商机!
大农化网报道: 生物制剂正成为农业领域增速最快的赛道之一,而《2026生物制剂专刊》能够将您的品牌置于这一行业对话的中心。 本期专刊汇聚了业内最具影响力的声音,深度聚焦突破性创新、新兴市场机遇和监管政策变化。无论您希望提升品牌知名度与公信力…
Nigeria Youth Agribusiness Fund to Empower 6 Million Nigerians
The Federal Government has launched the Youth in Agribusiness Land Trust Fund (YiALTF), a major initiative aimed at tackling youth unemployment, boosting food production, and improving access to farmland for young Nigerians.
解密2026生物制剂新风口,诚邀您的品牌共探商机!
世界农化网中文网报道: 生物制剂正成为农业领域增速最快的赛道之一,而《2026生物制剂专刊》能够将您的品牌置于这一行业对话的中心。
天津组织召开部署2026年“三夏”小麦机收工作视频会议 确保夏粮颗粒归仓
近日,为调度全市当前农业生产形势,进一步细化统筹做好“三夏”小麦机收各项服务保障工作,确保夏粮颗粒归仓,秋粮适时播种,天津市农业农村委员会组织召开部署2026年“三夏”小麦机收工作视频会议…
The biggest biotech funding rounds in May 2026
The companies Isomorphic Labs, Apogee Therapeutics, and Avalo Therapeutics bagged the biggest biotech funding rounds overall in May 2026 across private and public funding types. In this article, we break down last month’s private and public fundraising activity, looking at the largest rounds in more detail.
IMU Biosciences secures US$53m to decode the immune system
The round was co-led by IQ Capital and Molten Ventures, with participation from the British Business Bank, Meltwind and existing investors. IMU said the new capital will support operational expansion, further development of its clinical platform and infrastructure, and the advancement of clinical programmes in stem cell transplantation, solid organ transplantation and immuno-oncology.
Dammann files for bankruptcy
For the agricultural machinery industry in northern Germany, this move marks a turning point. Dammann has been regarded for decades as a specialist in liquids application. The company’s primary focus is on crop protection technology. In addition, its systems are used in vehicles for winter road maintenance and rail maintenance.
Abivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-off
Despite what some described as “the best placebo-adjusted clinical remission rates ever for a large Phase 3 study in ulcerative colitis,” analysts focused on emerging safety questions, including reported malignancy cases observed during the trial, sending the company’s shares sharply lower as investors reassessed the overall risk–benefit profile.
THIS Refreshes Wholefood Range with Mushroom “Tofu” and Crunchy Bites
London-based plant-based brand THIS has updated and expanded its wholefood range with two mushroom-based products now rolling out across major UK retailers, responding to consumer demand for cleaner-label, ingredient-led options.
